<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEXMETHYLPHENIDATE</span><br/>(dex-meth-ill-fen'i-date)<br/><span class="topboxtradename">Focalin, </span><span class="topboxtradename">Focalin XR<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">cerebral stimulant</span><br/><b>Prototype: </b>Amphetamine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg, 10 mg tablets; 5 mg, 10 mg, 20 mg extended release capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Thought to block the reuptake of norepinephrine and dopamine into the presynaptic neurons and, thereby, increasing release
         of these substances into the synapse. The mode of action in controlling the symptoms of attention deficit hyperactivity disorder
         (ADHD) by Focalin is not fully understood.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Focalin is used for control of ADHD syndrome in conjunction with other measures (psychological, educational, and social).
         The use of stimulants is contraindicated in patients who exhibit ADHD symptoms secondary to environmental factors, and/or
         other primary psychiatric disorders, including psychosis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Attention deficit hyperactivity disorder (ADHD).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to dexmethylphenidate or methylphenidate; severe agitation, anxiety, or tension; glaucoma; motor tics other
         than Tourette's syndrome; concurrent MAOI therapy; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate to severe hepatic insufficiency; Tourette's syndrome; depression; emotional instability; alcoholism or drug dependence;
         history of seizure disorders; psychotic symptomatology; hypertension or other cardiovascular disease; hyperthyroidism; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Attention Deficit Hyperactivity Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg b.i.d., may increase by 2.5 mg5 mg/d at weekly intervals to max of 20 mg/d. If converting from methylphenidate,
               start with ½ of methylphenidate dose. Extended release: 10 mg daily, may increase by 5 mg at weekly intervals to max of 20 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> &gt;<i>6 y</i>, 2.5 mg b.i.d., may increase by 2.5 mg5 mg/d at weekly intervals to max of 20 mg/d. If converting from methylphenidate,
               start with ½ of methylphenidate dose.  Extended release: 5 mg daily, may increase by 5 mg at weekly intervals to max of 20 mg/d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not administer with or within 14 d following discontinuation of a MAO inhibitor.</li>
<li>Give sustained release capsules whole. They should not be crushed or chewed.</li>
<li>Give b.i.d. doses at least 4 h apart.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, allergic reactions. <span class="typehead">CNS:</span> Dizziness, insomnia, nervousness, tics, abnormal thinking, hallucinations, emotional lability, CNS overstimulation or sympathomimetic
      effects [angina, anxiety, agitation, biting, blurred vision, delirium, diaphoresis, flushing or pallor, hallucinations, hyperthermia,
      labile blood pressure and heart rate (hypotension or hypertension), mydriasis, palpitations, paranoia, purposeless movements,
      psychosis, sinus tachycardia, tachypnea, or tremor]. <span class="typehead">CV:</span> Hypertension, tachycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain,</span> decreased appetite, nausea, vomiting. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive stimulant effects with other <span class="classification">stimulants</span> (including <b>amphetamine,</b>
<b>caffeine</b>); increased vasopressor effects with <b>dopamine,</b>
<b>epinephrine,</b>
<b>norepinephrine,</b>
<b>phenylpropanolamine,</b>
<b>pseudoephedrine;</b>
<span class="classification">mao inhibitors</span> may cause hypertensive crisis; antagonizes hypotensive effects of <b>guanethidine,</b>
<b>bretylium;</b> may inhibit metabolism and increase serum levels of <b>fosphenytoin,</b>
<b>phenytoin,</b>
<b>phenobarbital,</b>
<b>and primidone,</b>
<b>warfarin,</b>
<span class="classification">tricyclic antidepressants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> well absorbed. <span class="typehead">Peak:</span>  11.5 h.  <span class="typehead">Metabolism:</span> De-esterified in liver. No interaction with CYP450 system. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 2.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician if patient has a seizure. Monitor closely for loss of seizure control with a prior history
            of seizures.
         </li>
<li>Monitor BP in all patients receiving this drug. Monitor cardiac status and report palpitations or other signs of arrhythmias.</li>
<li>Monitor for potential abuse and dependence on this drug. Careful supervision is needed during drug withdrawal since severe
            depression may occur.
         </li>
<li>Lab tests: Periodic CBC, differential, platelet counts, and LFTs during prolonged therapy.</li>
<li>Concurrent drugs: Monitor patients on BP-lowering drugs for loss of BP control. Monitor plasma levels of oral anticoagulants
            and anticonvulsants; doses of these drugs may need to be decreased.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Withhold drug and report immediately any of the following signs of overdose: vomiting, agitation, tremors, muscle twitching,
            convulsions, confusion, hallucinations, delirium, sweating, flushing, headache, or high temperature.
         </li>
<li>Note that drug is usually discontinued if improvement is not observed after appropriate dosage adjustment over 1 mo.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>